Targets › CXCL12
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Dec 2028.
Chemoattractant active on T-lymphocytes and monocytes but not neutrophils. Activates the C-X-C chemokine receptor CXCR4 to induce a rapid and transient rise in the level of intracellular calcium ions and chemotaxis. (UniProt, P48061)
Open in Phaseline: the race on CXCL12, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| TME Pharma | Olaptesed Pegol (A12) Stromal cell-derived factor 1 inhibitor | CXCL12 | Phase 1 | Glioblastoma | Dec 2028 |
Glioblastoma (1)
mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.